The Epsilon Group (TEG) is a modeling, analytics, and simulation services company committed to improving the understanding and management of disease with the ultimate goal of improving healthcare development and delivery.
To this end, TEG provides proprietary bio-simulation services and software (SAAM II and UVA/Padova T1DMS) which enable physiologically-based modeling of a wide range of problems in the lab and translational research.
TEG’s primary area of expertise is glucose-insulin metabolism in health and disease – including Type 1, Type 2 and Pre- Diabetes. As such, TEG offers simulation and consulting services for development and optimization of diabetes-specific treatments, protocols, and devices using a specialized (and unique) toolkit. This toolkit features the UVA/Padova Type 1 Diabetes Metabolic Simulator (T1DMS) in conjunction with the FDA-accepted in silico patient population.
Additionally, TEG offers innovative software products that enable industrial and academic research groups to independently model and solve laboratory and disease management problems. Specifically:
The Simulation, Analysis and Modeling software (SAAM II) supports early stage research and discovery with a robust computational core, enabling even those with limited modeling experience to create models quickly and accurately. While applicable to a wide variety of dynamic systems, SAAM II has been applied extensively to complex pharmacokinetic and pharmacodynamic modeling to support the development and refinement of novel treatment strategies.
In conjunction with the SAAM II application, The Epsilon Group offers minimal models (and associated documentation) designed for application of SAAM II to specific problems in glucose-insulin metabolism, the so-called glucose-insulin minimal models. With SAAM II and such models, clinicians and researchers can analyze data from Intravenous Glucose Tolerance Tests (IVGTT), Oral Glucose Tolerance Tests (OGTT), and Mixed-Meal Tolerance Tests (MTT) to obtain fundamental metabolic information including insulin sensitivities, glucose effectiveness, and beta-cell responsivities. Such analyses enable the quantitative understanding of the complex relationship among beta-cell function, hepatic insulin extraction, and insulin action.
- The T1DMS software (noted above) is also available for distribution to investigators – including a smaller “sample” in silico patient population – for the purposes of examination, development, testing and optimization of effective diabetes treatment and management strategies.
How TEG Solutions can help you
Life Sciences and Pharma
Develop physiologically-based pharmacokinetic/pharmacodynamic models, test control algorithms, simulate clinical trials and examine outcomes to optimize therapy and eliminate non-viable solutions cost-effectively.
Simulate interventions and management of diabetes and related disease processes to optimize care delivery and disease management.
Utilize latest compartmental analysis and mathematical modeling techniques to educate future healthcare providers, engineers and researchers across many disciplines.